Adicet Bio, Inc. (1IJ)
XMUN 
Summary
1IJ Chart
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Here's Why You Should Add ACET Stock to Your Portfolio Now
Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
Adicet Bio, Inc. (1IJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Adicet Bio, Inc. ever had a stock split?
Adicet Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Chen Schor CEO | XMUN Exchange | US0070022076 ISIN |
| US Country | 102 Employees | 16 Sep 2020 Last Dividend | 30 Dec 2025 Last Split | 26 Jan 2018 IPO Date |
Overview
Adicet Bio, Inc. stands out as a prominent player in the biotechnology sector, specifically focusing on the clinical stage development of innovative therapies. Founded in 2014 and headquartered in Boston, Massachusetts, the company is pioneering in the exploration and creation of allogeneic gamma delta T cell therapies. These advanced treatments are designed to target and combat a variety of autoimmune diseases as well as cancer, marking a significant advancement in the realm of immunotherapy. Adicet Bio, Inc.'s approach involves engineering gamma delta T cells with chimeric antigen receptors (CARs), aiming to achieve long-lasting activity and therapeutic efficacy in patients suffering from these challenging conditions.
Products and Services
- ADI-001
ADI-001 represents the forefront of Adicet Bio, Inc.'s innovative efforts, being a pioneering product candidate within the company's portfolio. This allogeneic gamma delta T cell therapy is engineered to express a CAR that specifically targets CD20. Currently undergoing a Phase I clinical trial, ADI-001 is designed for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Its development symbolizes a promising advancement in the fight against lymphoma, offering a novel therapeutic option that harnesses the power of the immune system to target and eliminate cancer cells.
- ADI-270
Expanding its reach in the domain of CAR T cell therapy, Adicet Bio, Inc. is also advancing ADI-270, a highly specialized armored gamma delta CAR T cell product candidate. This therapy is under development to target renal cell carcinoma, along with other CD70+ solid tumor and hematological malignancies indications. By focusing on these particular cancer cells, ADI-270 aims to offer a targeted, immunotherapy-based approach to treating cancer, underscoring Adicet Bio, Inc.'s commitment to addressing a wide range of cancer types with cutting-edge and personalized treatments.
